Cochrane COVID-19 Study Register
Study record
NCT05043376First Published: 2021 Sep 14Updated Date: 2021 Sep 14

A Randomized, Open-labelled, and Controlled Clinical Trial to Study the Adjuvant Treatment Benefits of Probiotic Streptococcus Salivarius K12 to Prevent/Reduce Lung Inflammation in Mild-to-moderate Hospitalised Patients With COVID-19

  1. Study Type
  2. Interventional
  1. Study Aim
  2. Treatment and Management
  1. Study Design
  2. Parallel/Crossover
  1. Intervention Assignment
  2. Randomised
Reference record

Study to Investigate the Treatment Benefits of Probiotic Streptococcus Salivarius K12 for Mild-to-moderate COVID-19

King Edward Medical University
First Published (first received 2021 September 14) (
Trial registry record
No Results
This is a randomised, open-label and control clinical trial aimed to investigate the adjuvant treatment benefits of probiotic Streptococcus salivarius K12 in hospitalised mild-to-moderate patients with COVID-19 disease